Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-18
DOI
10.1007/s40262-020-00888-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction
- (2019) Asha J Kapetas et al. AAPS Journal
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- Therapeutic drug monitoring and tyrosine kinase inhibitors
- (2016) Pauline Herviou et al. Oncology Letters
- Drug Interactions between Nine Antifungal Agents and Drugs Metabolized by Human Cytochromes P450
- (2015) Toshiro Niwa et al. CURRENT DRUG METABOLISM
- Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support
- (2015) Richard T. Scheife et al. DRUG SAFETY
- Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone
- (2015) G E Nybakken et al. LEUKEMIA
- Inhibition of c-Kit by tyrosine kinase inhibitors
- (2014) A. Galanis et al. HAEMATOLOGICA
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
- (2013) I.-K. Park et al. BLOOD
- A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors
- (2013) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
- (2013) Kerstin Maria Kampa-Schittenhelm et al. Molecular Cancer
- Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
- (2013) R. N. Gunawardane et al. MOLECULAR CANCER THERAPEUTICS
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Impact of new prognostic markers in treatment decisions in acute myeloid leukemia
- (2009) Richard F Schlenk et al. CURRENT OPINION IN HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation